HCV EU infographic
Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.
Our latest market snapshot offers an introduction to the real world patient data collected by our Therapy Watch HCV study, providing you with an overview of HCV patient profiles and treatment pathways.
Click here to view our infographic »
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »
Pricing wars heat up over hepatitis C drugs
The race for better hepatitis C treatments is in full swing with the approval of another all-oral drug regimen. The U.S. Food and Drug Administration (FDA) approved AbbVie’s new multi-drug combination, Viekira Pak, on December 19 last year, heightening the competition in the hepatitis C arena.
Sovaldi, Gilead’s oral treatment for hepatitis C costing $1,000 per pill, was cleared in the U.S. in December 2013, followed by the FDA approval of Harvoni at a cost of $1,125 per pill in October of last year. These two new Gilead drugs were launched at prices of $84,000 and $94,500 respectively for a 12-week regimen. In a battle to grab market share, AbbVie’s rival hepatitis C drug Viekira Pak costs $83,319 for a standard 12-week regimen.
Investigating factors affecting time to initiation of hepatitis treatment
Following the Viral Hepatitis Congress 2014 in Germany where Darren Kottler presented a poster presentation, he shares some of the factors affecting time from diagnosis to initiation of therapy in hepatitis patients.
By analysing the factors that lead to a patient to be treated for hepatitis, Therapy Watch data can illustrate the key elements of the patient’s condition that lead to one patient being treated sooner than another.
World Hepatitis Day, 28th July 2014
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better.
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better. The ‘Think Again’ campaign encourages people to challenge our perceptions of hepatitis, and aims to get people thinking again about what they think they know (or don’t know) about the disease. As part of this we have been encouraged to send in pictures which have challenged us to think again about the world we live in, and what we can do to help spread the word about hepatitis.